Copyright
©The Author(s) 2023.
World J Clin Cases. Jun 6, 2023; 11(16): 3736-3749
Published online Jun 6, 2023. doi: 10.12998/wjcc.v11.i16.3736
Published online Jun 6, 2023. doi: 10.12998/wjcc.v11.i16.3736
Table 1 Drugs for the management of diabetic-cornea
| No. | Drug | Indication |
| 1 | Topical thymosin β4 | Non-healing epithelial defect |
| 2 | Topical autologous serum | Promote corneal wound healing |
| 3 | Topical CT-112 | Reduction in corneal barrier effect |
| 4 | Topical insulin | Quicker reepithelization after epithelial scraping for vitreoretinal surgeries |
| 5 | Topical insulin | Prevent sub-basal nerve plexus loss |
| 6 | Topical insulin | Promote wound healing |
| 7 | Topical ranirestat | Promote wound healing, control the expression of MMP-10 and integrin α3 expression |
| 8 | Injection IGF-1 | Prevention of stem cell loss and improve sub-basal nerve plexus density |
| 9 | Topical naltrexone | Normalize corneal epithelial wound healing, tear film, and corneal sensations |
| 10 | Nateglinide and glibenclamide | Inhibit descemet membrane changes |
| 11 | Ciliary neurotrophic factor | Improve epithelial stem cells, increase nerve density and promote epithelial healing |
| 12 | Topical nerve growth factor | Reduced apoptosis and inflammation |
| 13 | IL-1 antagonists | Reduced apoptosis, faster wound healing, sensory stimulation, improved Akt signaling |
| 14 | Substance P | Improved wound healing, reinnervation, and reactivation of EGFR/Akt signaling |
- Citation: Morya AK, Ramesh PV, Kaur K, Gurnani B, Heda A, Bhatia K, Sinha A. Diabetes more than retinopathy, it’s effect on the anterior segment of eye. World J Clin Cases 2023; 11(16): 3736-3749
- URL: https://www.wjgnet.com/2307-8960/full/v11/i16/3736.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i16.3736
